Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

NewAmsterdam Pharma Co N.V (NAMS) EBT Margin: 2023-2025

Historic EBT Margin for NewAmsterdam Pharma Co N.V (NAMS) over the last 3 years, with Sep 2025 value amounting to -20,691.09%.

  • NewAmsterdam Pharma Co N.V's EBT Margin fell 2063390.00% to -20,691.09% in Q3 2025 from the same period last year, while for Sep 2025 it was -627.28%, marking a year-over-year decrease of 3524.00%. This contributed to the annual value of -530.25% for FY2024, which is 72532.00% up from last year.
  • As of Q3 2025, NewAmsterdam Pharma Co N.V's EBT Margin stood at -20,691.09%, which was down 22,713.35% from -90.70% recorded in Q2 2025.
  • In the past 5 years, NewAmsterdam Pharma Co N.V's EBT Margin registered a high of -57.19% during Q3 2024, and its lowest value of -20,691.09% during Q3 2025.
  • Over the past 3 years, NewAmsterdam Pharma Co N.V's median EBT Margin value was -1,602.62% (recorded in 2023), while the average stood at -3,797.50%.
  • In the last 5 years, NewAmsterdam Pharma Co N.V's EBT Margin spiked by 543,869bps in 2024 and then slumped by 2,063,390bps in 2025.
  • Quarterly analysis of 3 years shows NewAmsterdam Pharma Co N.V's EBT Margin stood at -6,160.40% in 2023, then surged by 543,869bps to -721.71% in 2024, then slumped by 2,063,390bps to -20,691.09% in 2025.
  • Its EBT Margin was -20,691.09% in Q3 2025, compared to -90.70% in Q2 2025 and -1,327.30% in Q1 2025.